anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of this study is to see if a new group of imaging tests can help identify response to stage IV human epidermal growth factor receptor 2 positive (HER2+) breast cancer before and during treatment. This study will test a new method for monitoring treatment. The investigators will use \[18F\]-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) to look at previously diagnosed stage IV breast cancer and image up to three times during therapy. FDG is a non-natural amino acid with a radioactive tag that is used clinically for staging of disease. However, the role of FDG-PET/MRI for imaging response in breast cancer is not currently clear. PET/MRI is a new imaging technique that combines PET and MRI into a single study.
Study Design:

Subjects will be randomly assigned in a 1:1 ratio to receive either cobomarsen or vorinostat. Approximately 126 subjects (63 per arm) are expected to be enrolled. Cobomarsen will be administered in the clinic by 2-hr intravenous infusion on Days 1, 3, 5 and 8, and weekly thereafter. Vorinostat will be dispensed to study subjects and taken as a daily oral dose according to the manufacturer's labeled dosing instructions. Treatment will continue until the subject becomes intolerant, develops clinically significant side effects, progresses, or the trial is terminated. An interim analysis will be conducted after approximately 40 subjects have been followed for a minimum of approximately 6 months. Enrollment will be suspended until the completion of the interim analysis.
About half of all individuals who receive treatment for substance use disorders (SUD) relapse within a year. Stress and an individual's biological response to it are significant predictors of relapse. Thus, interventions that decrease stress and normalize an individual's biological response to stress are desperately needed. Exercise decreases stress and improves the body's regulation of stress. The proposed project will utilize exercise as a novel relapse prevention intervention with individuals who have recently completed inpatient SUD treatment. This project will evaluate the efficacy of a motivational intervention for exercise in a randomized clinical trial of 150 SUD patients beginning Aftercare treatment at the VA St. Louis Health Care System. Participants will be randomized to one of two interventions: (1) standard care (SC), or (2) standard care plus a motivational intervention targeting exercise that lasts for six months. Participants are followed every three months for one year. Results from this study will advance exercise as a new strategy for enhancing stress regulation and prevention of relapse in SUD populations.
Xiaochaihu Decoction(XCHD)is a classic prescription for the treatment of fever, but the mechanism is not clear. In this study, We elucidated the mechanism of action through network pharmacology and molecular docking. A rat fever model was established to verify the prediction results of network pharmacology. The analysis revealed that 120 intersection targets existed between XCHD and fever. The TP53, STAT3, RELA, MAPK1, AKT1, TNF and MAPK14 as potential core targets of XCHD in fever treatment. GO and KEGG pathway enrichment analyses indicated that XCHD may act through pathways such as the AGE-RAGE signaling pathway in diabetic complications, TNF signaling pathway, IL-17 signaling pathway. Molecular docking results demonstrated that quercetin, kaempferol, β-sitosterol, stigmasterol and baicalein exhibited strong binding activity to key targets. Animal experiments showed that XCHD significantly reduced body temperature and levels of IL-1β, IL-6, TNF-α, NO, PGE2, and cAMP in rats with fever. Importantly, no significant difference was observed between the XCHD self-emulsifying nano phase plus suspension phase and XCHD group. XCHD exerts its therapeutic effects on fever through a multi-ingredient, multi-target, and multi-pathway approach.
Male and female subjects of 12 years of age and older with a history suggesting nasal allergic symptoms for at least 1 year. Patients must be symptomatic at screening.
The invention discloses a drug for treating puerperium haemorrhage. The drug comprises the following components: 10 parts-30 parts of pseudo-ginseng, 30 parts-50 parts of Chinese angelica, 10 parts-30 parts of peach seeds, 10 parts-30 parts of bupleurum, 10 parts-30 parts of stigma croci, 5 parts-15 parts of Yunnan white powder, 10 parts-30 parts of hairyvein agrimony, 10 parts-30 parts of bletilla, 10 parts-15 parts of callicarpa undiflora and the like, wherein the pseudo-ginseng, the Chinese angelica, the peach seeds, the Yunnan white powder, the callicarpa undiflora and the like are main drugs. The pseudo-ginseng, the Chinese angelica, the peach seeds, the Yunnan white powder, the callicarpa undiflora and the like have the functions of hemostasis, antibiosis, diminishing inflammation and replenishing blood, can effectively stop bleeding to prevent a puerpera from shocking or threat to life caused by losing the blood too much, and can have the functions of antisepsis, anti-inflammation and preventing infection and a complication from causing. In addition, the pseudo-ginseng, the Chinese angelica, the peach seeds, the Yunnan white powder, the callicarpa undiflora and the like can replenish the blood effectively, and improve the habitus and an immunity of a patient. Not only can the disease be promoted to recover, but also the quality of milk can be guaranteed. The patient and an infant can both receive the benefit. The other Chinese herbal medicinal ingredients can not only guarantee respective pesticide effect after being manufactured to be apozem, but also supplement each other and take advantages from each other. The state of an illness of bleeding can be effectively suppressed, and the recovery of the state of the illness is promoted.
The invention comprises compounds of the general formula <FORM:0779500/IV(b)/1> wherein R is an alkyl group containing from 1 to 6 carbon atoms, and R1 and R11 are alkanoyl groups, which may be the same or different, containing from 1 to 6 carbon atoms, and their preparation by acylation of the corresponding diamino compounds or, when the group R1 and R11 are different, the corresponding monoamino-monoacylamino compounds.  The acrylation is carried out by heating with the appropriate acid, acid anhydride or acid halide.  It is pre-ferable to use formic acid for the formation of the formyl derivative and the appropriate acid anhydride or acid halide for the formation of higher derivatives.  The acylation is promoted by the addition of a trace of a strong acid such as sulphuric acid, perchloric acid or an organic sulphonic acid.  Examples describe the preparation of (1) the ethyl, methyl, propyl, isopropyl and butyl esters of 3,5-diacetamino-2,4,6-triiodobenzoic acid by acrylation of the corresponding esters of 3,5-diamino-2,4,6-triiodobenzoic acid with acetic anhydride in the presence of a trace of concentrated sulphuric acid; (2) ethyl 3,5-diformamido-2,4,6-triiodobenzoate by heating the corresponding diamino compound with formic acid; (3) ethyl 3,5-dipropionamido-2,4,6-triiodobenzoate by heating the corresponding diamino compound with propionic anhydride or propionyl chloride; the butyramido compound is obtained similarly; (4) ethyl-3-formamido-5-acetamino - 2,4,6 - triiodobenzoate by heating ethyl 3 - amino - 5 - acetamido - 2,4,6 - triiodo benzoate with formic acid; and (5) ethyl 3-propionamido - 5 - acetamido - 2,4,6 - triiodobenzoate by heating ethyl 3-amino-5-acetamido-2,4,6-triiodobenzoate with propionic anhydride. The products are stated to be useful as X-ray contrasting agents. Starting materials.  Esters of 3,5-diamino-2,4,6-triiodobenzoic acid are prepared by catalytic reduction of the corresponding ester of 3,5-dinitrobenzoic acid followed by exhaustive iodination of the resulting 3,5-diamino benzoic acid ester with iodine monochloride in acid solution.  Esters of 3-amino-5-acylamino-2,4,6-triodobenzoic acid are prepared as follows: 3,5-dinitrobenzoic acid is selectively reduced to 3-nitro-5-amino-benzoic acid which is then acylated to a 3-nitro-5-acylaminobenzoic acid.  This is then esterified and the ester is catalytically hydrogenated to give an alkyl 3-amino-5-acrylamino benzoate which is exhaustively iodinated, conveniently with a solution of potassium iodide dichloride (KIbl2).ALSO:A radiopaque agent contains as an active ingredient a compound of the formula <FORM:0779500/VI/1> where in R is an alkyl group containing from 1 to 6 carbon atoms and R1 and R11 are the same or different alkanoyl groups each containing from 1 to 6 carbon atoms.  The active ingredient may be dispersed in a finely divided dust or it may be made into an aqueous suspension with the aid of an emulsifying agent such as carboxymethylcellulose, polyvinyl-pyrrolidone or dextran.
The invention relates to a biologically active composition, which can be used both for treating chronic wounds and for cosmetic purposes. The product solves the problem of accelerating the healing process of wounds of various origin and condition. The biologically active composition, according to the invention, contains a relatively low concentration of alkaline proteinaceous-collagen hydrolysate stabilized in glycerin gel, magnesium and zinc ions, vitamins, antiseptics. The product created this way has a wide range of application and a number of positive effects, which makes the product multifunctional. The proposed combination of substances seemingly acting in opposite directions allows for the recovery of the previously known as non-healing chronic wounds, even in patients suffering from diabetes or poor blood flow (arterial insufficiency), while at the same time it can also be used for a variety of skin blemishes such as stings, inflammation from burning or insects, for various hematomas from blows, lichens or scabs due to psoriasis, etc. 3 claims
Following baseline, participating outlets in this arm will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback for 3 months. After 3 months they will receive no further intervention, but will continue to receive Pseudo-Intoxicated Mystery Shops (P-I/MS).
PROBLEM TO BE SOLVED: To obtain the subject composition giving a temporary sealing material, etc., for dental use having sufficiently high hardness durable to biting pressure and high sealability without using complicate procedures such as heating by using an organopolysiloxane having a specific viscosity as a base material. SOLUTION: This composition is composed of (A) 100 pts.wt. of an organopolysiloxane containing >=2 aliphatic unsaturated hydrocarbon groups in one molecule and having a viscosity of 50-1,000 cSt at 25 deg.C, (B) 0.1-40 pts.wt. of an organohydrogen polysiloxane having >=3H atoms directly bonded to silicon atom in one molecule, (C) 10-500ppm (based on A+B) of a platinum compound soluble in silicone, (D) 10-400 pts.wt. of an inorganic filler and (E) 5-50 pts.wt. of fine silica powder having hydrophobicized surface and a BET specific surface area of 50-500m<2> /g.
Zolpidem tartrate extended-release tablets are not recommended for use in children. Safety and effectiveness of zolpidem in pediatric patients below the age of 18 years have not been established.

In an 8-week study in pediatric patients (aged 6 to 17 years) with insomnia associated with attention-deficit/hyperactivity disorder (ADHD) an oral solution of zolpidem tartrate dosed at 0.25 mg/kg at bedtime did not decrease sleep latency compared to placebo. Psychiatric and nervous system disorders comprised the most frequent (>5%) treatment emergent adverse reactions observed with zolpidem versus placebo and included dizziness (23.5% vs 1.5%), headache (12.5% vs 9.2%), and hallucinations were reported in 7% of the pediatric patients who received zolpidem; none of the pediatric patients who received placebo reported hallucinations [see Warnings and Precautions (5.5)]. Ten patients on zolpidem (7.4%) discontinued treatment due to an adverse reaction.

FDA has not required pediatric studies of zolpidem tartrate extended-release tablets in the pediatric population based on these efficacy and safety findings.
Novel compounds are disclosed having the structure of Formula I. The compounds are potent bacterial efflux pump inhibitors (EPis). Such compounds are useful to potentiate the antimicrobial activity of antimicrobial compounds such as beta-lactam antibiotics and quinolone antibiotics against Gram-negative bacteria. These novel compounds are effective as antibiotic or antimicrobial potentiators. Structures of these compounds are distinctive from other reported efflux pump inhibitors and antibiotic potentiators. Also disclosed are methods for inhibiting bacterial efflux pumps with the novel compounds described herein. In another embodiment, the present invention discloses the use of these novel compounds for the inhibition of bacterial efflux pumps. In yet another embodiment, the present invention discloses the use of these novel compounds for treating or inhibiting bacterial infection.
FIELD: medicine, immunology, microbiology. SUBSTANCE: strain Salmonella typhimurium T-10 BMC160 is obtained from the strain Salmonella typhimurium T-10. Using genetic transformation plasmid pBMC160 providing synthesis of protein g160 of human immunodeficiency virus is incorporated into the parent strain. Strain Salmonella typhimurium T-10 BMC160 shows high capacity to induce expressed and effective immunization to human immunodeficiency virus. Strain is used for development of immunity against human immunodeficiency virus. EFFECT: valuable properties of strain. 3 tbl, 3 ex
The invention discloses an application of a small molecular compound with a structure shown in the following formula in preparing a medicine for resisting SARS-CoV-2 infection, belonging to the pharmaceutical field. The experimental result shows that the compound can effectively inhibit SARS-CoV-2 3CLpro activity and has dose-effect relationship, and has half Inhibitory Concentration (IC) on SARS-CoV-2 3CLpro  50  ) 8.932. Mu.M. For SARS-CoV-2 real virus, the semi-Inhibitory Concentration (IC)  50  ) 2.21. Mu.M. Therefore, the compound can be used as a candidate inhibitor of SARS-CoV-2 3CLpro to inhibit the replication of SARS-CoV-2, and has application prospect in the preparation of anti-SARS-CoV-2 infection medicines.
The investigators will recruit 30 cognitively-normal elderly and 30 elderly with Mild Cognitive Impairment(MCI) and 30 elderly with Subjective Cognitive Decline(SCD). Participants will be randomly assigned to one of three groups: sequential training (first perform physical exercise followed by cognitive training), simultaneous training (perform physical exercise and cognitive tasks simultaneously), and control group (perform body stretching and health education courses). All participants will receive trainings for 120 minutes per day, one day per week for 12 weeks. The outcome will include measurements that evaluate the cognitive, physical, daily functions, quality of life, and social participation. Participants will be assessed at baseline, after the intervention, and at 3-month follow-up. Repeated measures of analysis of variance (ANOVA) will be used to evaluate the changes in outcome measures at three different time points for the elderly with cognitively-normal, Mild Cognitive Impairment(MCI) and Subjective Cognitive Decline(SCD), respectively. The investigators also use the analysis of covariance (ANCOVA) to investigate the differences between the Mild Cognitive Impairment(MCI) and Subjective Cognitive Decline(SCD) groups on the outcome measures.
PROBLEM TO BE SOLVED: To obtain an antioxidant excellent in an effect to suppress photooxidation by compounding a specific titanium dioxide as an active ingredient and to obtain a cosmetic capable of suppressing peroxide generation on the skin by using the antioxidant. SOLUTION: This antioxidant is composed of a titanium dioxide which contains one, or more kinds selected from oxidants of metals other than titanium in an amount of 1-20 wt.% based on the total weight of the powder among crystal lattices of titanium dioxide. It is preferable to select the metals other than titanium from iron, zinc, aluminum, cobalt, magnesium, zirconium, etc. The surface of the antioxidant is preferably treated by silica coating, etc., or treated with a silylating agent, etc. This antioxidant is preferably applied especially to a makeup cosmetic. The content of the antioxidant in a cosmetic is 0.1-40 wt.%. This cosmetic is especially suitable as a summer cosmetic.
BACKGROUND Foreign body aspiration (FBA) is a common and serious problem in childhood that requires early recognition and treatment. Common complications include asphyxia, hemorrhage, infection, and pneumothorax. In severe cases of foreign body obstruction, death can result from asphyxia. We report an interesting case in which a forgotten cotton ball was inhaled into the lungs. CASE REPORT A 5-year-old boy presented to the local hospital with coughing for 6 days and fever for 4 days, without any information of foreign body aspiration upon admission. Laboratory findings indicated an elevated white blood cell; therefore, cefprozil was given as anti-infective treatment. However, the child's condition did not improve. A computed tomography scan showed left pulmonary atelectasis. Considering that the child's condition was serious, he was referred to our hospital for diagnosis and treatment. After referral, auscultation revealed decreased breath sounds over the left lung. After multidisciplinary discussion, combined with the results of auxiliary examination, the possibility of a foreign body was considered. He underwent rigid bronchoscopy, which confirmed a yellow-white foreign body in the left main bronchus that was later verified as a cotton ball. The operation was very successful. Eventually, his condition improved and he was discharged, without additional complications. CONCLUSIONS For children with unclear history of foreign body aspiration, bronchoscopy is recommended if there is recurrent pulmonary infection, low auscultation breath sounds, or abnormal imaging. The choice of surgical method depends on the location and type of foreign body and the experience of the surgeon, which is also very important.
Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the Substantia nigra pars compacta (SNpc). Apoptosis is thought to play a critical role in the progression of PD, and thus understanding the effects of antiapoptotic strategies is crucial for developing potential therapies. In this study, we developed a unique genetic model to selectively delete Casp3, the gene encoding the apoptotic protein caspase-3, in dopaminergic neurons (TH-C3KO) and investigated its effects in response to a subacute regime of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration, which is known to trigger apoptotic loss of SNpc dopaminergic neurons. We found that Casp3 deletion did not protect the dopaminergic system in the long term. Instead, we observed a switch in the cell death pathway from apoptosis in wild-type mice to necrosis in TH-C3KO mice. Notably, we did not find any evidence of necroptosis in our model or in in vitro experiments using primary dopaminergic cultures exposed to 1-methyl-4-phenylpyridinium in the presence of pan-caspase/caspase-8 inhibitors. Furthermore, we detected an exacerbated microglial response in the ventral mesencephalon of TH-C3KO mice in response to MPTP, which mimicked the microglia neurodegenerative phenotype (MGnD). Under these conditions, it was evident the presence of numerous microglial phagocytic cups wrapping around apparently viable dopaminergic cell bodies that were inherently associated with galectin-3 expression. We provide evidence that microglia exhibit phagocytic activity towards both dead and stressed viable dopaminergic neurons through a galectin-3-dependent mechanism. Overall, our findings suggest that inhibiting apoptosis is not a beneficial strategy for treating PD. Instead, targeting galectin-3 and modulating microglial response may be more promising approaches for slowing PD progression.
An aq. dispersion of fluorocarbon-contg. phospholipid vesicles comprises an aq. dispersion contg. phospholipid vesicles of lamellar layer structure in which are enclosed one or more oxygen transporting fluorocarbons in a concn. of 2-100% w/v. in a cage like structure, the phospholipid vesicles having a uniform particle size of 80-400nm. USE/ADVANTAGE - Used as a gas transporting medium and as a diagnostic in biological systems both in vivo and in vitro. They can be mixed with electrolytes, energy carriers and onkotic substances as artificial blood special oxygen-transporting pharmaceutical prepns. for the treatment of shock, cardiac infarction and cerebral ischaemia. They can also be used to support radio- and chemotherapy of malign tumours and as a contrast agent in X-ray, magnetic resonance and ultrasound diagn
Disclosed is a method of using: a) an aromatic alcohol of Formula (I) where R1 is a linear or branced C1-C10 alkylene group , and b) at least one menthyl ester of Formula (II) wherein R2 denotes a C1-C4 alkyl group to improve the odour inhibiting effect of cosmetic agents over a period of about 24 to 48 hours. Also claimed is a composition comprising compounds of Formulas (I) and (II) and at least one deodorant ingredient. Most preferably, (I) is 2-methyl-4-phenyl-2-butanol and (II) is menthyl acetate (i.e. R2 = methyl, CH3). Preferably, the at least one deodorising compound is either triethyl citrate or phenoxyethanol. Also claimed is a cosmetic product comprising (I), (II) and a deodorant ingredient and, further, at least one propellant (e.g. aerosol). A method of using the composition of (I), (II) and a deodorising ingredient for reduction of body odour caused by sweat is also claimed. Worked embodiments of the deodorant are free of aluminium salts.
PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
PURPOSE: A raloxifene-containing solid dispersing material is provided to ensure solubility of hydrochloric acid raloxifeen with high stability. CONSTITUTION: A raloxifene-containing solid dispersing material is obtained by moving an inactive carrier in granulation. The solid dispersing material has 5% or less of LOD(loss of drying) at 105°C. A crystal hydrochloric acid raloxifene is obtained by dissolving the crystal hydrochloride acid in methanol, water, or acetone. The crystal hydrochloride raloxifene additionally contains a binder. A tabletizing material is acquired by tabletizing the raloxifene-containing solid dispersing agent with the pharmaceutically acceptable additives.
NEW MATERIAL:A platinum complex whose carrier is an acidic polysaccharide containing a saccharide having at least one of a COO<-> group and a -SO <-> group as a constituting saccharide. EXAMPLE:Cis-dichloro-trans-(1,2-cylohexanediamine)platinum-chondroitin -sulfuric acid complex. USE:An antitumor agent. PREPARATION:For example, a diamine (e.g., 1,2-cylohexanediamine) is dissolved in water and mixed with a potassium platinous chloride aqueous solution to react with each other to form a cis-dichloro-diamine platinum complex (II). The complex is suspended in water and mixed with a silver nitrate aqueous solution and the produced precipitates are filtered off. The remained filtrate is reacted with an acidic polysaccharide (e.g., chondroitin-sulfuric acid) containing a saccharide having at least one of a COO<-> group and a SO group to provided the platinum complex.